5-AMP-Activated Protein Kinase, Gamma-2 Subunit (PRKAG2) Mutation Analysis
PRKAG2 gene is located in the long (q) arm of chromosome 7 at position 36.1 and encodes 5-AMP-activated protein kinase, gamma-2 subunit. AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine protein kinase consisting of one catalytic subunit (α) a non-catalytic subunit (β) and a regulatory subunit (γ) that exist as multiple isoforms and splice variants. AMPK is an energy sensing protein kinase that plays a key role in regulating cellular energy metabolism. This protein is activated during times of cellular stress (such as low oxygen levels or muscle exercise), when ATP is broken down rapidly to produce energy. If ATP levels become too low, the enzyme restores the balance of energy by limiting chemical reactions that require ATP and stimulating pathways that generate ATP. AMP, ADP, or ATP can bind the AMPK γ subunit to regulate AMPK activation through allosteric structural changes in the catalytic α subunit, modulating phosphorylation by upstream kinases and preventing dephosphorylation of catalytic subunits. Most commonly, missense mutation is identified in PRKAG2.
Mutations in this gene are most commonly missense mutations and have been associated with familial hypertrophic cardiomyopathy (FHCM), Wolff-Parkinson-White syndrome, and glycogen storage disease of the heart.
FHCM is an autosomal dominant genetic heart disorder characterized by unexplained left ventricular (LV) hypertrophy (thickening) associated with non-dilated ventricular chambers. Pathological features include myocardial fiber hypertrophy, disorganized myocardial cells, interstitial fibrosis and thickened intra-myocardial coronary vessels. The majority of FHCM patients are asymptomatic. Only about 25% develop symptoms such as dyspnea, syncope, collapse, palpitations, and/or chest pain. The disorder has inter- and intra-familial variability ranging from benign to malignant forms with a high risk of cardiac failure and sudden cardiac death. FHCM is the most common cause of sudden cardiac death in young people and has a prevalence of 1:500 in the general adult population. There are numerous genetic mutations associated with FHCM, most are associated with sarcomere genes (TNNT2, TNNI3, MYL2, MYL3, MYBPC3, MYH7, ACTC1, TPM1 and perhaps others. FHCM caused by mutations in PRKAG2 are uncommon and found in only 1 in 200 patients with left ventricular hypertrophy.
Wolff-Parkinson-White (WPW) syndrome is a condition in which there is an extra electrical pathway in the heart that allows electrical signals from the atria to bypass the atrioventricular (AV) node and therefore arrive at the ventricles too quickly. The condition can lead to periods of tachycardia (rapid heart rate) and is one of the most common causes of and abnormally fast heart rate in infants and children.
- Diagnostic confirmation of Wolff-Parkinson-White (WPW) syndrome
- Diagnosis of familial hypertrophic cardiomyopathy
- To identify at-risk family members, provide reproductive risks as well as preconception/prenatal options
Positive
- Mutation or pathogenic variant in PRKAG2 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.
Negative
- No mutation or pathogenic variant detected in PRKAG2 gene
Negative for mutations analyzed (No mutation or pathogenic variant detected)
Whole blood (EDTA).
Stability
- Ambient: 72 hours
- Refrigerated: 1 week
- Frozen: Unacceptable
- Methods Mol Biol. 2018;1732: 581-619. [PMID: 29480501]
- BMC Med Genet. 2018;19:1. [PMID: 29298659]
- Cell Res. 2016; 26: 1099-1111. [PMID: 27573176]
- Circ Arrhythm Electrophysiol. 2016;9: e003121. [PMID: 26729852]
- Cardioskeletal Myopathies in Children and Young Adults, In: Chapter 15, Cardio Skeletal Muscle Disease Associated With
- Syndromes. 2017: 307-329. doi:10.1016/b978-0-12-800040-3.00015-7